Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-13

Alamar Biosciences, Inc. (ALMR) Stock Forecast Oct. 13, 2026

Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D Neutral Alpha
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Middle 30% of 5379 stocks scored
Rank correlation · 90D n/a No per-ticker sample yet
Market Cap $1.63B small-cap · #10 of 25 peers
Summary

Alamar Biosciences, Inc. (ALMR) stock forecast summary

On Oct. 13, 2026, ALMR is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.

Alamar Biosciences, Inc. is a small-cap company with a market capitalization of $1.63B. It ranks number 10 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.

A per-ticker accuracy statistic for ALMR is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, ALMR included.

Follow ALMR free
Price

ALMR price chart and AI forecast

ALMR
Cross-section · 2026-10-13

How ALMR ranks among 5379 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals

Alamar Biosciences, Inc. (ALMR) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.

Valuation & Market

MetricALMRIndustry medianRank
Market Cap $1.63B $500M 10/25
P/B Ratio 5.22x 2.47x 5/23
Book Value/Share $4.51 – –

Financial Health

MetricALMRIndustry medianRank
Current Ratio 11.85x 3.14x 3/25
Quick Ratio 10.23x 2.06x 2/24
D/E Ratio 0.25x 0.47x 19/24
Financial Leverage 1.25x 1.48x 19/24
Interest Coverage -92.0x -22.1x 18/21
Working Capital $303M $147M 9/25

Dividend & Shareholder Information

MetricALMRIndustry medianRank
Shares Outstanding 69M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$331M84.8% of assets
Cash & Short-term Investments$133M34.0% of assets
Accounts Receivable$20M5.2% of assets
Inventory$45M11.6% of assets
Total Liabilities$78M20.0% of assets
Short-term Debt$14M3.6% of assets
Quarterly Financial Reports

ALMR quarterly financials and insider trading

Industry Peers · Laboratory Analytical Instruments

Alamar Biosciences, Inc. (ALMR) industry peers

Companies classified under the same SEC industry code as Alamar Biosciences, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
ALMR Alamar Biosciences, Inc. ▶ $1.63B – 5.2x
A Agilent Technologies, Inc. ▼ $48.40B 33.6x 6.6x
WAT Waters Corp /De/ ▲ $42.17B – 2.8x
ILMN Illumina, Inc. ▶ $40.95B 49.6x 14.4x
MTD Mettler Toledo International Inc/ ▼ $32.02B 35.4x –
RVTY Revvity, Inc. ▼ $17.30B 72.9x 2.4x
AVTR Avantor, Inc. ▶ $10.62B – 1.8x
BIO Bio-Rad Laboratories, Inc. ▼ $9.73B 43.7x 1.4x
TXG 10x Genomics, Inc. ▲ $9.35B – 11.3x
BRKR Bruker Corp ▲ $8.56B – 3.6x
CTKB Cytek Biosciences, Inc. ▲ $695M – 2.2x
PACB Pacific Biosciences Of California, Inc. ▲ $637M – –
MASS 908 Devices Inc. ▲ $500M – 3.9x
EYPT Eyepoint, Inc. ▲ $265M – 1.6x
NAUT Nautilus Biotechnology, Inc. ▲ $261M – 2.0x
BFNH Bioforce Nanosciences Holdings, Inc. ▼ $250M – 108.7x
QTRX Quanterix Corp ▲ $149M – 0.6x
SEER Seer, Inc. ▶ $119M – 0.4x
RPID Rapid Micro Biosystems, Inc. ▲ $44M – 2.5x
PRPO Precipio, Inc. ▲ $40M – 2.7x
HBIO Harvard Bioscience Inc ▼ $38M – 5.1x
BNGO Bionano Genomics, Inc. ▲ $16M – 0.5x
LCTC Lifeloc Technologies, Inc ▲ $11M – 2.9x
ASTC Astrotech Corp ▶ $11M – 0.7x
SCND Scientific Industries Inc ▲ $8M – 1.0x

Where ALMR sits on the market map

Industrial Applications and Services · Laboratory Analytical Instruments
Explore the map →
News

Alamar Biosciences, Inc. (ALMR) stock news

Loading...

FAQ

Alamar Biosciences, Inc. (ALMR) stock forecast FAQ

What is the Alamar Biosciences, Inc. (ALMR) stock forecast?

On Oct. 13, 2026, ALMR is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.

How accurate are Alamar Biosciences, Inc. stock predictions?

A per-ticker accuracy statistic for ALMR is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Alamar Biosciences, Inc. forecasts updated?

Alamar Biosciences, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.

Which companies are Alamar Biosciences, Inc.'s industry peers?

25 issuers in our coverage, ALMR included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.